What's wrong with our cancer models?
Top Cited Papers
- 1 February 2005
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 4 (2) , 161-165
- https://doi.org/10.1038/nrd1635
Abstract
Oncology, as a therapeutic area, is characterized by a desperate medical need for new drugs; the use of drugs that kill cells and which are consequently often toxic; and rates of failure in expensive Phase III trials that eclipse many other disease areas. The poor performance of most investigational cancer drugs implies that the standard preclinical disease models are faulty or, at least, improperly used. Some studies, however, support the view that cancer models can be highly effective, but only when selected and interpreted with care.Keywords
This publication has 17 references indexed in Scilit:
- Development of TGF-β signalling inhibitors for cancer therapyNature Reviews Drug Discovery, 2004
- Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical TrialsJAMA, 2004
- Toward large-scale modeling of the microbial cell for computer simulationJournal of Biotechnology, 2004
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- Predictive factors for epidermal growth factor receptor inhibitors—The bull's-eye hits the arrowCancer Cell, 2004
- Integrating pharmacology and in vivo cancer models in preclinical and clinical drug developmentEuropean Journal Of Cancer, 2004
- Imatinib as a Paradigm of Targeted TherapiesPublished by Elsevier ,2004
- Consequences of Nonadaptive Alterations in CancerMolecular Biology of the Cell, 2003
- Molecular mechanisms of resistance to STI571 in chronic myeloid leukemiaCurrent Opinion in Hematology, 2002
- STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implicationsOncogene, 2001